The CD146− CAFs are reported to suppress estrogen receptor expression in breast cancer cells and increase the resistance to tamoxifen therapy, while CD146+ CAFs restore the sensitivity of cancer cells to tamoxifen treatment. Here, MCAM is linked to breast carcinoma.